9.68
Organon Co (OGN) 最新ニュース
Co. stock movementJuly 2025 Rallies & Stepwise Entry/Exit Trade Alerts - Newser
Organon & Co. shares rise 3.45% intraday after HKEX censures Henlius Biotech, rebukes former CEO. - AInvest
Organon And Henlius Are Latest To Receive Denosumab Nod In US - insights.citeline.com
Organon and Henlius get FDA nod for Amgen biosimilars (OGN) - Seeking Alpha
US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively - Yahoo Finance
Major Breakthrough: FDA Approves Two New Biosimilars to Treat Millions with Bone Health Conditions - Stock Titan
A | What is the PEG ratio of Organon & Co.Quarterly Market Summary & Free Weekly Chart Analysis and Trade Guides - khodrobank.com
Organon's Upside Potential: Can Biosimilars and Women’s Health Drive a Re-rating? - AInvest
Will Raised Revenue Guidance and New Launches Shift Organon's (OGN) Growth Outlook? - simplywall.st
How Investors Are Reacting To Organon (OGN) Lifting 2025 Guidance and CEO Share Purchase - Yahoo Finance
Organon & Co. (OGN) Advances VTAMA Cream, Strengthens Women’s Health Portfolio - MSN
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know - MSN
Organon & Co. shares rise 1.57% intraday after Trane Technologies launches Season 5 of Healthy Spaces podcast. - AInvest
Organon & Co. shares fall 1.02% intraday after Genentech files BPCIA complaint against Organon and Henlius. - AInvest
Henlius And Organon Sued In US Over Plans To Market Perjeta Biosimilar - insights.citeline.com
Does Organon's Raised 2025 Guidance Signal a Turning Point for OGN Investors? - simplywall.st
Kahn Brothers' Q2 2025 13F Filing: Alphabet, Comcast, and Organon Highlights - AInvest
Organon in charts: Women's Health revenue up ~3% Y/Y in Q2 - MSN
Roche Sues Organon in First Case Over Biosimilar Copy of Perjeta - Bloomberg Law News
There May Be Some Bright Spots In Organon's (NYSE:OGN) Earnings - Yahoo Finance
Organon & Co. (OGN) Stock Price, News & Analysis - MarketBeat
Daré Bioscience Posts Narrower Q2 Loss - The Motley Fool
OGN’s Market Whiplash: -52.64% YTD Decline, -4.30% Plunge in 30 Days - investchronicle.com
Bullish Organon Insiders Loaded Up On US$651.6k Of Stock - 富途牛牛
Organon & Co.'s Q2 2025 Earnings Call: Unraveling Key Contradictions in Capital Allocation, Nexplanon Growth, and Financial Forecasts - AInvest
LPL Financial LLC Has $4.87 Million Holdings in Organon & Co. (NYSE:OGN) - Defense World
NYSE: OGN Lawsuit Alert: Investors who lost money with Organon & Co. (NYSE: OGN) shares should contact the Shareholders Foundation - The Malaysian Reserve
Ex-Dividend Reminder: Cencora, Organon and Esquire Financial Holdings - Nasdaq
5 Must-Read Analyst Questions From Organon’s Q2 Earnings Call - Yahoo Finance
OGN Q2 Deep Dive: Flat Sales, Margin Pressure, and Strategic Shifts Highlight Quarter - Yahoo Finance
Organon's Valuation: Discounted Due to Structural Challenges - AInvest
Organon: Valuation Discount Offset By Structural Headwinds (NYSE:OGN) - Seeking Alpha
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know - MSN
Natixis Advisors LLC Has $778,000 Holdings in Organon & Co. (NYSE:OGN) - Defense World
Organon & Co. (OGN): Assessing Dividend Sustainability and Valuation Amid Earnings Pressures and Strategic Catalysts - AInvest
Read This Before Considering Organon & Co. (NYSE:OGN) For Its Upcoming US$0.02 Dividend - uk.finance.yahoo.com
Organon & Co. (OGN) Reports Q2 2025 Results - MSN
Organon Q2 Preview: What to expect? - MSN
Organon & Co. (NYSE:OGN) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Organon & Co. Reports Q2 2025 Earnings, Raises Full-Year Guidance - AInvest
Organon & Co. (NYSE:OGN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
Organon & Co. Reports Q2 2025 Financial Results - The Globe and Mail
Organon & Co. Earnings Call: Resilience Amid Challenges - The Globe and Mail
Organon (OGN) Fiscal Q2 Revenue Beats 1% - AOL.com
Organon & Co. (OGN) Slashes 13.13% on Disappointing Earnings - MSN
Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade) (NYSE:OGN) - Seeking Alpha
Endometriosis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Biosciences - The Globe and Mail
Organon & Co. SEC 10-Q Report - TradingView
Organon & Co. (NYSE:OGN) Q2 2025 Earnings Call Transcript - Insider Monkey
Organon jumps despite Q2 revenue dip as revised outlook exceeds consensus - MSN
Organon Reports Results for the Second Quarter Ended June 30, 2025 - BioSpace
ORGANON SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co.OGN - Discover 361
大文字化:
|
ボリューム (24 時間):